Rheumatology
Rheumatology
Advertisement
Mithu Maheswaranathan, MDOsteoarthritis | February 5, 2024
It is critical for physicians to be confident and comfortable in diagnosing and managing knee osteoarthritis.
Read More
Dr. Mark BleackleyRheumatology | February 2, 2024
Incannex announces the first dosing in a phase 2 study of a novel drug combination comprising HCQ and CBD to treat RA.
Rob DillardAI | January 16, 2024
Artificial intelligence can potentially detect rheumatic heart disease with the same level of accuracy as a cardiologist.
Mithu Maheswaranathan, MDRheumatology | December 22, 2023
Mithu Maheswaranathan, MD, spoke about challenges, treatments, and trends in rheumatology, as well as upcoming advancements.
Mithu Maheswaranathan, MDRheumatology | December 6, 2023
A study aimed to create a benefit-versus-harm shared decision-making tool for hydroxychloroquine for patients with SLE.
Rebecca AraujoRheumatoid Arthritis | November 27, 2023
Having multiple risk factors for cardiovascular disease may increase the risk of rheumatoid arthritis treatment failure.
Rebecca AraujoRheumatoid Arthritis | November 9, 2023
Recent safety data significantly impacted prescribing practices for advanced RA therapies among physicians treating veterans.
Rebecca AraujoRheumatology | November 3, 2023
For adults with lupus nephritis, this specific treatment combination improves total remission rate better than others.
Rebecca AraujoRheumatology | October 24, 2023
Bimekizumab demonstrated sustained efficacy for the treatment of active axial spondyloarthritis through 52 weeks.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
A study provided a unique characterization of a rare: large-vessel involvement from ANCA-associated vasculitis.
Mithu Maheswaranathan, MDRheumatoid Arthritis | October 11, 2023
A study sought to identify variables distinguishing inflammatory from noninflammatory arthritis in a large cohort.
Patrick DalyRheumatoid Arthritis | July 26, 2023
Abatacept improved outcomes for rheumatoid arthritis refractory to methotrexate or TNFi versus rituximab or tocilizumab.
Mithu Maheswaranathan, MDRheumatoid Arthritis | October 11, 2023
Ultra-low dose rituximab significantly reduced the rate of infections versus the standard low dosage in rheumatoid arthritis.
Rebecca AraujoRheumatology | July 17, 2023
Individuals with systemic lupus erythematosus face a substantial economic burden in the first 12 months following treatment.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
Researchers examined changes in objective measures of cardiorespiratory function and patient-reported outcomes in lupus.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
A study sought to characterize racial differences in lupus clinical manifestations.
Rebecca AraujoRheumatoid Arthritis | June 5, 2023
The American College of Rheumatology has released new recommendations for the management of rheumatoid arthritis.
Rebecca AraujoRheumatology | June 2, 2023
A study reported an increased psychiatric morbidity burden in patients with juvenile idiopathic arthritis.
Patrick DalyRheumatoid Arthritis | May 30, 2023
Patients with rheumatoid arthritis with lower hemoglobin levels may be more likely to have increased progression over time.
Patrick DalyRheumatoid Arthritis | May 16, 2023
Researchers established tranexamic acid was safe and effective in patients with rheumatoid arthritis following TKA.
Advertisement
Advertisement
Advertisement
Latest News

March 1, 2024